Adults with type 2 diabetes may be more likely to report smell and taste disturbances if they were prescribed a GLP-1 receptor agonist, according to data published in JAMA Otolaryngology – Head & Neck Surgery.
In an analysis of data from the TriNetX electronic health records database, researchers compared smell and taste disturbances among adults with type 2 diabetes who were prescribed a GLP-1 with those who had no history of GLP-1 use.
“The substantial effects of GLP-1 receptor agonists on weight regulation and eating behavior raised the possibility that they may also influence taste and

Patients with Alzheimer’s disease experienced rapid and significant improvements in agitation with a combination of CBD and THC, according to an abstract presented at the Alzheimer’s Association International Conference.
Approximately half of patients with dementia approaching the end of their life exhibit agitation, and symptoms persist for more than a third despite treatment, Jacobo Mintzer, MD, a psychiatrist with the Ralph H. Johnson VA Healthcare System in South Carolina, and colleagues wrote.
“This is a robustly positive, randomized, controlled trial that represents a major step forward

Nephrologists in Canada are attending to a greater number of inpatients with more complex conditions compared with other medical specialties, according to study data published in the American Journal of Kidney Diseases. 
Several factors may contribute to increasing complexity of chronic kidney disease and higher patient volume in nephrology, such as the rising prevalence of CKD and greater recognition of CKD globally, according to Anukul Ghimire, MD, MSc, a clinical fellow at the University of Toronto, Marcello Tonelli, MD, SM, MSc, professor at the University of Calgary Cumming School of

Among pediatric patients with eosinophilic esophagitis, around a quarter had joint hypermobility, according to results published in The Journal of Allergy and Clinical Immunology.
Researchers went on to find that this group of patients had a significantly higher score on a questionnaire measuring autonomic symptoms vs. those without hypermobility, signaling greater symptom severity.
“Our study highlights a vital need for clinicians to screen for autonomic symptoms and hypermobility,” Joshua B. Wechsler, MD, MSCI, medical director of the eosinophilic gastrointestinal diseases program at Lurie

Jennifer Bickel, MD, had established herself as a nationally respected headache specialist by the time she assumed a new leadership role at Children’s Mercy Hospital in 2018.
While serving as medical director for the institution’s Center for Wellbeing, she implemented system changes and developed programs that promoted a culture of belonging and supported staff resilience.
Two years later, she led a team charged with supporting the well-being of staff members amid the COVID-19 pandemic.
Those experiences sparked a new passion and prompted her to pivot.
She left her clinical role in 2021 to become

The FDA has granted breakthrough therapy designation to enpatoran for lupus with active skin manifestations, according to a press release from EMD Serono.
The designation comes in the wake of the phase 2, placebo-controlled WILLOW study, in which enpatoran (EMD Serono), an oral selective toll-like receptor (TLR) 7/8 inhibitor, demonstrated significant and dose-dependent impacts on disease activity in patients with active skin manifestations of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus. The study also found the drug well tolerated among patients.
“For the 85% of